Monthly Prescribing Reference: ‘MK3’ Fixed-Dose Combination Effective in HCV GT 1, 2, and 3

November 2, 2016
 

A fixed-dose combination of pangenotypic direct-acting antivirals was “‘highly effective” in treatment-native patients with hepatitis C virus (HCV) genotypes (GT) 1, 2, and 3, a study presented at The Liver Meeting (R) 2016 has shown. Read the full story at Monthly Prescribing Reference

Read more

Express-News: Researchers encourage Hispanic women to join clinical trials for breast cancer treatments

September 20, 2016
 

Despite the fact that breast cancer is the most common and deadly cancer among Hispanic women, little is known about the types of breast cancer Hispanics are likely to get or how they react to treatments. Read the full story at the Express-News

Read more

San Antonio Business Journal: SA drug discovery center will use state money to expand cancer research

August 10, 2016
 

The Center for Innovative Drug Discovery has big plans for its latest cash infusion — nearly $4.6 million courtesy of a new grant from the Cancer Prevention and Research Institute of Texas. Read the full story at the San Antonio Business Journal

Read more

Dr. Lillian Liao

Express-News: Hot cars in San Antonio can be deadly for unattended children

July 5, 2016
 

After sitting under the scorching sun on a 95 degree afternoon, the inside of a black Chevy Suburban reached a temperature high enough to fry an egg on the dashboard. Safe Kids San Antonio, in partnership with the Texas Heatstroke Task Force and the Southwest Texas Regional Advisory Council parked the car in the sun […]

Read more


Time Warner Cable News: San Antonio Home to PTSD Treatment Program

July 5, 2016
 

Doctors are stressing the importance of getting help for anyone who suffers from post-traumatic stress disorder. Experts at the University of Texas Health Science Center say data shows 80 percent of PTSD patients can be treated to the point of recovery using therapy. Watch the full story at Time Warner Cable News

Read more

MedPage Today: Revisiting Neoadjuvant Hormones for ER+ Breast Cancer

July 5, 2016
 

Neoadjuvant endocrine therapy for estrogen receptor (ER)-positive breast cancer achieved response rates similar to those obtained with combination chemotherapy but with less toxicity, pooled data from 20 studies showed. The findings have implications for a majority of women with newly diagnosed early breast cancer, most of which is ER-positive disease. Clinical experience in the adjuvant […]

Read more